Metformin for the Prevention of Oral Cancer in Patients With Oral Premalignant Lesions
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This phase I trial tests whether metformin works in reducing the annual transformation
(development of invasive cancer) of oral precancerous lesions into cancerous lesions.
Metformin is a drug approved for the treatment of diabetes, but studies have shown that it
may have some anticancer properties. Giving metformin may help prevent or slow the
development of oral cancer from precancerous lesions.